Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab
Hickish T, Wheatley D, Lin N, Carey L, Houston S, Mendelson D, Solca F, Uttenreuther-Fischer M, Jones H, Winer E. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. Journal Of Clinical Oncology 2009, 27: 1023-1023. DOI: 10.1200/jco.2009.27.15_suppl.1023.Peer-Reviewed Original ResearchHER2-positive metastatic breast cancerPhase II studyMetastatic breast cancerBIBW 2992Tyrosine kinase inhibitorsPartial responseBreast cancerEpidermal growth factor receptorStable diseaseAdverse eventsII studyDisease progressionTumor assessmentOpen-label single-arm phase II studySide effectsEastern Cooperative Oncology Group performance statusSingle-arm phase II studyHER2-positive breast cancer patientsDual epidermal growth factor receptorArm phase II studyTrastuzumab-resistant cell linesEGFR/HER2 tyrosine kinase inhibitorHER2-positive breast cancerHER2 tyrosine kinase inhibitorAdequate organ function